Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3800657 | 0.80 | TDP1 (0.31) | TDP1 | |
| SCHEMBL1816137 | 0.77 | TSHR (0.46) | TDP1 | |
| SCHEMBL19465648 | 0.74 | CHRNB2 (0.46) | CYP2D6CYP2C19 | |
| SCHEMBL5620325 | 0.73 | — | — | |
| SCHEMBL5620333 | 0.73 | — | — | |
| SCHEMBL28564887 | 0.73 | CYP2D6 (0.44) | CYP2D6CYP2C19TDP1POLB | |
| SCHEMBL11381892 | 0.71 | ALDH1A1 (0.31) | — | |
| SCHEMBL4241010 | 0.70 | — | — | |
| SCHEMBL1897647 | 0.70 | — | — | |
| SCHEMBL4632651 | 0.70 | MEN1 (0.34) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2212330-B1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (3) | CHOONGWAE PHARMA CORP (KR) | 2015-04-08 | — | — | EP | claimed |
| US-8080657-B2 | Compounds of reverse turn mimetics and the use thereof | CHOONGWAE PHARMA CORPORATION (KR) | 2011-12-20 | — | — | US | claimed |
| US-7932384-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2011-04-26 | — | — | US | claimed |
| US-20100286094-A1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF | CHOONGWAE PHARMA CORPORATION (KR) | 2010-11-11 | — | — | US | claimed |
| US-20100228027-A1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (2) | CHOONGWAE PHARMA CORPORATION (KR) | 2010-09-09 | — | — | US | claimed |
| EP-2212329-A2 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (1) | Choongwae Pharma Corporation (KR) | 2010-08-04 | — | — | EP | claimed |
| EP-2212328-A2 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (2) | Choongwae Pharma Corporation (KR) | 2010-08-04 | — | — | EP | claimed |
| EP-2212330-A2 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (3) | Choongwae Pharma Corporation (KR) | 2010-08-04 | — | — | EP | claimed |
| WO-2009051397-A9 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (3) | CHOONGWAE PHARMA CORPORATION (KR) | 2010-05-27 | — | — | WO | claimed |
| US-7671054-B1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2010-03-02 | — | — | US | claimed |
| US-20100029630-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | Chongwae Pharma Corporation (KR) | 2010-02-04 | — | — | US | claimed |
| US-7566711-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2009-07-28 | — | — | US | claimed |
| WO-2009051399-A2 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (1) | CHOONGWAE PHARMA CORPORATION (KR) | 2009-04-23 | — | — | WO | claimed |
| WO-2009051397-A2 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (3) | CHOONGWAE PHARMA CORPORATION (KR) | 2009-04-23 | — | — | WO | claimed |
| WO-2009051398-A2 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (2) | CHOONGWAE PHARMA CORPORATION (KR) | 2009-04-23 | — | — | WO | claimed |
| US-20070043052-A1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-02-22 | — | — | US | claimed |
| EP-1740588-A2 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | Choongwae Pharma Corporation (KR) | 2007-01-10 | — | — | EP | claimed |
| WO-2005116032-A2 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2005-12-08 | — | — | WO | claimed |
| US-10092568-B2 | CBP/Catenin antagonists for enhancing asymmetric division of somatic stem cells | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2018-10-09 | — | — | US | disclosed |
| EP-1264824-A1 | Preparation of alkyl-N-(3-dimethylamino)alkylcarbamates | Aventis CropScience GmbH (DE) | 2002-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286094-A1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF | MCL1, MYADM, FLT3 | CYP2D6 3485/4885CYP2C19 4243/4885RECQL 2114/4885 |
| US-20100029630-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, APC, WNT3 | CYP2D6 4684/4885CYP2C19 4819/4885RECQL 4388/4885 |
| US-20100228027-A1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (2) | MCL1, BID, MYADM | CYP2D6 4073/4885CYP2C19 4559/4885RECQL 3061/4885 |
| US-20070043052-A1 | Reverse-turn mimetics and method relating thereto | WNT1, APC, WNT3 | CYP2D6 4684/4885CYP2C19 4819/4885RECQL 4388/4885 |
| US-10092568-B2 | CBP/Catenin antagonists for enhancing asymmetric division of somatic stem cells | WNT3A, WNT1, CTNNA1 | CYP2D6 4831/4885CYP2C19 4860/4885RECQL 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.